A retrospective study analysing EGFR inhibition in EGFR-amplified esophagogastric cancer
Latest Information Update: 12 Nov 2021
At a glance
- Drugs Cetuximab (Primary) ; Depatuxizumab (Primary) ; Gefitinib (Primary) ; Nivolumab (Primary) ; Panitumumab (Primary) ; Antineoplastics; Protein tyrosine kinase inhibitors
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 12 Nov 2021 New trial record
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress